What is the recommended milrinone loading (bolus) dose and infusion protocol, and how should it be adjusted for hypotension, severe arrhythmias, high‑dose beta‑blockers, or renal impairment?

Milrinone Bolus Dosing

Administer milrinone as a 50 mcg/kg loading dose over 10 minutes, followed by a continuous infusion of 0.375–0.75 mcg/kg/min, but omit the bolus in hypotensive patients (systolic blood pressure <85–100 mmHg) to avoid precipitous blood pressure drops. 1, 2, 3

Standard Dosing Protocol

Loading Dose

• 50 mcg/kg administered slowly over 10 minutes 1, 2, 4, 3
• May be given undiluted or diluted to 10–20 mL for easier visualization of injection rate 3
• The bolus provides immediate hemodynamic effects with maximal changes in cardiac index (+0.97 L/min/m²) and pulmonary capillary wedge pressure (−11.25 mmHg) occurring immediately after loading 5

Maintenance Infusion

• Standard rate: 0.5 mcg/kg/min 1, 2, 4, 3
• Range: 0.375–0.75 mcg/kg/min 2, 4, 6, 3
• Maximum: 0.75 mcg/kg/min (total daily dose should not exceed 1.13 mg/kg/day) 2, 3
• Dilute to 200 mcg/mL concentration using 0.45% or 0.9% sodium chloride, or 5% dextrose 3

Critical Adjustments for Specific Clinical Scenarios

Hypotension Management

In patients with systolic blood pressure <100 mmHg, initiate therapy WITHOUT a bolus dose to prevent excessive vasodilation and hypotension. 2, 4, 6

• The European Society of Cardiology guidelines specifically recommend omitting the bolus in hypotensive patients (SBP <100 mmHg) 2, 4
• Starting infusion without bolus still achieves significant hemodynamic effects by 30 minutes, with similar pulmonary capillary wedge pressure reduction (−8.6 mmHg) by 2 hours compared to bolus strategy 5
• One study documented marked hypotension requiring discontinuation in a patient who received a bolus, supporting the no-bolus approach in borderline blood pressure 5

Severe Arrhythmias

• Milrinone may cause less tachycardia than dobutamine 1
• However, increased ventricular ectopy can occur: premature ventricular complexes increased from 87/hr to 141/hr, couplets from 6.0/hr to 14.3/hr, and runs from 0.9/hr to 2.7/hr in one study 7
• Two of 12 patients (17%) met criteria for proarrhythmia (>4× increase in PVCs or >10× increase in repetitive forms), though neither required dose reduction 7
• Use with caution in patients with baseline high-grade ventricular arrhythmias; consider alternative inotropes if sustained ventricular tachycardia develops 7

High-Dose Beta-Blocker Therapy

Milrinone is preferred over dobutamine in patients on concurrent beta-blocker therapy because its mechanism of action (phosphodiesterase-3 inhibition) is distal to beta-adrenergic receptors. 2, 8, 4

• The ESC guidelines give this a Class IIa recommendation (Level of Evidence C) 8
• Milrinone maintains its inotropic and vasodilating effects even during concomitant beta-blockade 2, 4
• Standard dosing applies; no adjustment needed for beta-blocker use 2, 4

Renal Impairment Dosing

For patients with renal dysfunction, reduce the maintenance infusion rate according to creatinine clearance, but the loading dose remains unchanged at 50 mcg/kg. 3, 9

The FDA label provides specific infusion rate reductions based on creatinine clearance 3:

• CrCl 50 mL/min: 0.43 mcg/kg/min
• CrCl 40 mL/min: 0.38 mcg/kg/min
• CrCl 30 mL/min: 0.33 mcg/kg/min
• CrCl 20 mL/min: 0.28 mcg/kg/min
• CrCl 10 mL/min: 0.23 mcg/kg/min
• CrCl 5 mL/min: 0.2 mcg/kg/min

A validated study in moderate (CrCl 31–75 mL/min) and severe (CrCl 10–30 mL/min) renal impairment demonstrated that infusion rates of 0.45 and 0.35 mcg/kg/min, respectively, achieved therapeutic steady-state concentrations (239 and 269 ng/mL) without serious adverse events 9

Important caveat: Recent evidence suggests milrinone may be less effective in patients who develop acute kidney injury during cardiogenic shock, with attenuation of clinical benefit compared to dobutamine 10. In patients with severe renal dysfunction (CrCl <30 mL/min or on dialysis), levosimendan was associated with worse outcomes than milrinone, suggesting milrinone remains a reasonable choice in this population 11.

Hemodynamic Monitoring and Titration

• Target mean arterial pressure ≥65 mmHg 1
• Invasive monitoring may be necessary to accurately measure hemodynamic parameters 1
• Titrate to maximum hemodynamic effect based on cardiac output and pulmonary capillary wedge pressure 3
• Use calibrated electronic infusion device for continuous administration 3
• Therapeutic plasma concentration range: 100–300 ng/mL 9

Common Pitfalls to Avoid

• Do not give bolus in hypotensive patients: This is the most critical error, as the vasodilatory effects can cause precipitous blood pressure drops requiring discontinuation 2, 4, 5
• Do not use in hypovolemia: Milrinone is relatively contraindicated until volume status is corrected, as vasodilation will worsen hypoperfusion 2, 4
• Avoid in severe aortic or mitral stenosis: Vasodilators should be used with caution in significant valvular stenosis 6
• Monitor for thrombocytopenia: Though uncommon (0.4%), this adverse effect can occur 8
• Recognize accumulation in renal failure: The terminal elimination half-life significantly increases with renal impairment, necessitating dose reduction 3, 9
• Caution in ischemic heart failure: Safety concerns exist particularly in patients with coronary artery disease, as phosphodiesterase inhibitors may increase medium-term mortality 4